InVivo Biosystems: 10 Key Things You Must Know

Overview

InVivo Biosystems is a cutting-edge biotechnology company headquartered in Eugene, Oregon. They specialize in developing custom genome-edited models using C. elegans and zebrafish, primarily focusing on aging, neurological, and metabolic diseases. Since its inception in 2010 (initially known as NemaMetrix), InVivo Biosystems has become a pivotal player in preclinical drug discovery, utilizing their proprietary RapidGen™ platform. This article explores ten key insights into the company, uncovering why it stands out in the biotech landscape and how it is pushing the frontiers of research innovation.

1. Genesis and Evolution

InVivo Biosystems was founded by Drs. Shawn Lockery and Janis Weeks at the University of Oregon in 2010, originally under the name NemaMetrix. It emerged from innovative research using microfluidic techniques to study C. elegans, a model organism crucial for genetic studies. In 2017, the company expanded by merging with Knudra Transgenics, enhancing its capabilities in CRISPR gene editing. This merger solidified its position as a leading provider of transgenic models tailored for specific research applications.

2. RapidGen™ Platform

Central to InVivo Biosystems' success is the RapidGen™ platform. This comprehensive preclinical platform has revolutionized drug discovery by expediting the predictive modeling of diseases. It allows researchers to glean vital insights quicker by employing advanced genome-editing technologies that bridge the gap between cellular studies and rodent models, particularly in areas like oncology and neurodegeneration.

3. Zebrafish and C. elegans Models

InVivo Biosystems leverages zebrafish and C. elegans to create innovative research models. Zebrafish are particularly valuable due to their vertebrate status, ease of genetic modification, and high degree of genetic similarity to humans—making them ideal for studying complex human diseases, drug toxicity, and developmental biology. Similarly, C. elegans are used to explore genetic pathways due to their well-mapped genome and transparent body, facilitating in vivo observation.

4. Focus on Neurological Disorders

The company has made significant inroads into neurological disorder research. By creating specific models for central nervous system diseases, including epilepsy and Alzheimer's, InVivo Biosystems provides critical tools for understanding and developing treatments for these conditions. This focus reflects a broader industry trend towards personalized medicine based on genetic insights.

5. Leadership and Vision

In 2024, InVivo Biosystems underwent a leadership transition that injected new strategic vision into the company. Under the leadership of CEO Kat McCormick, the company continues to extend its global reach. The leadership is keen on leveraging emerging technologies and expanding the company’s services to better assist partners in the pharmaceutical, nutraceutical, and academic sectors.

6. CRISPR Genome Editing

InVivo Biosystems is at the forefront of CRISPR technology application, holding multiple patents on genome editing techniques. Their expertise in this area not only enhances their research capabilities but also offers clients cutting-edge tools to conduct robust genetic research, paving the way for potential breakthroughs in drug discovery and developmental biology.

7. Partnerships and Collaborations

Collaboration is a key strategy for InVivo Biosystems, seen in its partnerships with institutions and industry leaders. The company frequently co-sponsors webinars and workshops that emphasize the application of its models in innovative research. These collaborations enhance its reputation and enable shared learning and advancements in biotechnology.

8. Funding and Investment

InVivo Biosystems has benefitted from significant venture capital investment and grant funding. As of early 2024, the company secured $3M in their latest funding round. Its strategic investors include reputable entities like the National Institutes of Health and the Oregon Venture Fund, underscoring investor confidence in its business model and future potential.

9. Commitment to Diversity and Inclusion

Beyond its scientific endeavors, InVivo Biosystems prides itself on fostering an inclusive workplace culture. The company actively promotes diversity, equity, and inclusion as core values, believing these principles drive innovation and reflect the communities they serve. This ethos not only enhances corporate culture but also promotes a dynamic and innovative working environment.

10. Future Prospects

Looking ahead, InVivo Biosystems aims to expand its service offerings and continue refining its technologies to stay on the cutting edge of the biotechnology industry. With a growing emphasis on the application of AI in biomedicine, the company is poised to further integrate artificial intelligence into their research processes, enhancing data analytics and developing more precise models for drug discovery and disease research.

Conclusion

InVivo Biosystems stands out in the biotechnology field as a leader in custom genome engineering and disease modeling. The company's innovative approaches, driven by state-of-the-art technologies like CRISPR and the RapidGen™ platform, have far-reaching implications for drug discovery and genetic research. As they continue to expand and innovate, InVivo Biosystems is not only accelerating scientific understanding but also advancing global health solutions.